Tammisetti VS, Prasad SR, Dasyam N, Menias CO, Katabathina V. Immunosuppressive therapy in solid organ transplantation: primer for radiologists and potential complications. Radiol Clin North Am. 2023;61(5):913–32.
…
Author: admin
-
BAE Systems, Boeing and Saab to Collaborate on Next-Gen Pilot Training – BAE Systems
- BAE Systems, Boeing and Saab to Collaborate on Next-Gen Pilot Training BAE Systems
- Boeing says partnership for T-7 trainer export bid imminent Reuters
- Boeing, Saab, and BAE Plot Trainer Jet Power Move–Hawk Successor Could Shake Up Market TradingView
- BAE Systems ties up with Boeing, Saab for UK jet trainer bid MarketScreener
- Boeing hints at new alliance as U.K. eyes Hawk replacement (BA:NYSE) Seeking Alpha
Continue Reading
-
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Strengthens Intellectual Property Portfolio and Provides Protection for Therapeutic Combination in Acclaim-3 Clinical Trial
AUSTIN, Texas, Nov. 18, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex a patent that covers the use of the Company’s lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®, through 2037.
“We continue to build protection around our lead drug candidate, REQORSA, and this new patent provides the necessary technology protection applicable to our Acclaim-3 clinical trial in small cell lung cancer,” said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. “In the Acclaim-3 clinical trial, we are combining REQORSA with Tecentriq, a PD-L1 antibody, and this patent secures exclusivity for this drug combination for the treatment of cancer, preventing would-be competitors from making, using or selling this drug combination.”
Genprex has been granted patents for the use of REQORSA in combination with PD-L1 antibodies in the U.S. and Korea. Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China and Israel. Should these applications grant, they would also be applicable to Genprex’s Acclaim-3 clinical trial.
PD-L1 antibodies are a type of targeted immunotherapy that block the activity of PD-L1 immune checkpoint proteins present on the surface of cells.
About Acclaim-3
Acclaim-3 is a Phase 1/2 clinical trial evaluating the combination of REQORSA and Genentech’s Tecentriq® (atezolizumab) as maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC) who are candidates for maintenance therapy after receiving Tecentriq and chemotherapy as standard of care initial treatment. In this study, patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.The Phase 2 expansion study follows the successful completion of the Phase 1 dose escalation portion of the study, which showed REQORSA was generally well tolerated. There were no dose limiting toxicities, and in Acclaim-3, the Phase 2 patients are receiving the same dose of REQORSA as patients in the Phase 2 portion of Acclaim-1.
The Phase 2 expansion portion is expected to enroll approximately 50 patients. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. Genprex’s team plans to conduct an interim analysis after the 25th patient enrolled and treated reaches 18 weeks of follow up. The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the first half of 2026. The Acclaim-3 clinical trial is supported by U.S. Food and Drug Administration (FDA) Fast Track Designation and Orphan Drug Designation.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex’s lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K for the year ended December 31, 2024.Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex’s ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex’s clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status, including Genprex’s ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex’s commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex’s intellectual property and licenses, including the potential for future grants of patent applications globally; and Genprex’s current expectations, estimates, forecasts and projections about the industry and markets in which it operates.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)GNPX Investor Relations
[email protected]GNPX Media Contact
Kalyn Dabbs
[email protected]SOURCE Genprex, Inc.
Continue Reading
-
Chinese scientists solve 70-year cosmic ray origin mystery
A group of scientists from China, together with space researchers from other countries, has discovered that the formation of cosmic rays in the Milky Way is influenced by microquasars – systems consisting of a black hole and a…Continue Reading
-
Just a moment…
Just a moment… This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
Continue Reading
-
Has Samsung Installed ‘Unremovable Israeli Spyware’ On Your Phone?
What are the facts behind the new spyware furor.
AFP via Getty Images
Updated Nov. 18 with Samsung’s response to the AppCloud controversy.
You may not have seen the headlines yet — but you will. There’s a furor building on social media with…
Continue Reading
-
Relationships among mediterranean diet adherence, sustainable food literacy, and depression in healthcare professionals | BMC Health Services Research
Comparisons of participants’ Mediterranean Diet Adherence Screener (MEDAS) scores, sustainable food literacy subdimensions (knowledge I and II, food and culinary skills, attitudes, action strategies, and total score), and total BECK scores were…
Continue Reading
-
Better late than never! 18 characters whose late arrival lifted TV shows | Television
Welcome. Nice of you to finally join us. Hope it was worth the wait. Yes, sometimes a late addition can improve a drama or comedy so much it becomes hard to imagine the show without them. Not every series gets the casting chemistry spot-on…
Continue Reading
-
Vertiv and Caterpillar Announce Energy Optimization Collaboration to Expand End-to-End Power and Cooling Offerings for AI Data Centers
New agreement aims to enhance data center efficiency, resiliency and deployment timelines through integrated energy solutions.
COLUMBUS, Ohio, Nov. 18, 2025 /PRNewswire/ — Vertiv (NYSE: VRT), a global leader in critical digital infrastructure, and Caterpillar Inc. (NYSE: CAT), a global leader in power systems, today announced the signing of a strategic undertaking to collaborate on advanced energy optimization solutions for data centers. This initiative will integrate Vertiv’s power distribution and cooling portfolio with Caterpillar’s, and its subsidiary Solar Turbines’, product and expertise in power generation and CCHP (Combined Cooling, Heat and Power) to deliver pre-designed architectures that simplify deployment, accelerate time-to-power and optimize performance for data center operations.
Vertiv and Caterpillar announce a collaboration to enhance data center efficiency, resiliency and deployment timelines through integrated energy solutions.
A Powerful Collaboration:
This collaboration directly addresses the growing demand for on-site energy solutions that deliver reliable power and cooling. Together, the companies are able to offer a fully integrated solution with validated interfaces and performance, enabling customers to accelerate design, installation and deployment.- Caterpillar and Solar Turbines will supply power generation solutions, such as natural gas turbines and reciprocating engines, to deliver dependable, scalable electric power and thermal energy for CCHP.
- Vertiv will provide a complete portfolio of power and cooling solutions and services, packaged as modular, pre-designed blocks, to shorten design cycles and standardize deployment.
The Customer Advantages:
- Accelerates Time-to-Power – by utilizing predesigned, modular reference architectures to speed up deployment time.
- Lowers PUE (Power Usage Effectiveness) – enables improved energy efficiency and carbon footprint because the system is optimized end-to-end: power, cooling, distribution and dynamic load management, compared to traditional design.
- Global lifecycle support – the offering is backed by the trusted, global service and support networks of both Vertiv and Caterpillar.
“This collaboration with Caterpillar and Solar Turbines is a cornerstone of our Bring Your Own Power & Cooling (BYOP&C) strategy and aligns seamlessly with our grid-to-chip framework by offering resilient, on-site power generation solutions. This is optimal for customers looking to reduce or eliminate grid dependence,” said Gio Albertazzi, CEO, at Vertiv. “By combining our complementary technologies, portfolios and expertise, we are enabling coordinated integration. Our pre-engineered, interoperability-tested building blocks let customers execute design, build and deploy concurrently, with predictable system performance.”
“As AI-driven workloads continue to accelerate, the demand for robust and scalable power infrastructure and cooling is becoming increasingly critical,” said Jason Kaiser, group president of Caterpillar Power & Energy. “Our collaboration with Vertiv will enable us to deliver integrated, on-site energy solutions that lower PUE and meet customers’ evolving needs.”
This initiative directly addresses the growing demand for on-site energy solutions and offers a coordinated, customer-first approach to solution design and implementation. The Vertiv and Caterpillar Memorandum of Understanding (MOU) represents a pivotal step in further refining this ecosystem, enabling customers to overcome energy constraints and deploy optimized AI centers.
To learn more about Vertiv’s end-to-end power and thermal management solutions, visit Vertiv.com.
To learn more about the Caterpillar capability, visit Caterpillar.com / SolarTurbines.com.About Vertiv
Vertiv (NYSE: VRT) brings together hardware, software, analytics and ongoing services to enable its customers’ vital applications to run continuously, perform optimally and grow with their business needs. Vertiv solves the most important challenges facing today’s data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Headquartered in Westerville, Ohio, USA, Vertiv does business in more than 130 countries. For more information, and for the latest news and content from Vertiv, visit Vertiv.com.About Caterpillar
With 2024 sales and revenues of $64.8 billion, Caterpillar Inc. is the world’s leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. For 100 years, we’ve been helping customers build a better, more sustainable world and are committed and contributing to a reduced-carbon future. Our innovative products and services, backed by our global dealer network, provide exceptional value that helps customers succeed. Caterpillar does business on every continent, principally operating through three primary segments – Construction Industries, Resource Industries and Energy & Transportation – and providing financing and related services through our Financial Products segment. Visit us at caterpillar.com or join the conversation on our social media channels.About Solar Turbines
Solar Turbines Incorporated, headquartered in San Diego, is a wholly owned subsidiary of Caterpillar Inc. Solar manufactures the world’s most widely used family of mid-sized industrial gas turbines from the 1 – 39 MW range. More than 15,000 Solar units are operating in 100 countries around the world. Primary applications include electric power generation, oil and natural gas production and natural gas transmission.Forward-looking statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27 of the Securities Act, and Section 21E of the Securities Exchange Act. These statements are only a prediction. Actual events or results may differ materially from those in the forward-looking statements set forth herein. Readers are referred to Vertiv’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q for a discussion of these and other important risk factors concerning Vertiv and its operations. Vertiv is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.VERTIV CONTACT
[email protected]CATERPILLAR CONTACT
[email protected]SOURCE Vertiv Holdings Co
Continue Reading
-
Ex-Anthony Joshua sparring partner offers to help Jake Paul
British heavyweight Lawrence Okolie has offered to help Jake Paul prepare for his fight against Anthony Joshua and spar with the YouTuber-turned-boxer.
The Paul-Joshua bout, a professional eight-round contest using 10-ounce gloves in Miami, was…
Continue Reading